Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.

"CONFLICT OF INTEREST STATEMENT Harmony Leroy, no conflict of interest; Noémie Gadaud, no conflict of interest; Emilie Bérard, no conflict of interest; Emilie Klein, no conflict of interest; Isabelle Luquet, no conflict of interest; Jean‐Philippe Vial, no conflict of interest; Jean‐Baptiste Rieu, no conflict of interest; Nicolas Lechevalier, no conflict of interest; Tavitian, no conflict of interest; Thibaut Leguay, no conflict of interest; Laetitia Largeaud, no conflict of interest; Audrey Bidet, no conflict of interest; Eric Delabesse, no conflict of interest; Audrey Sarry, no conflict of interest; Anne‐Charlotte de Grande, no conflict of interest; Christian Récher: report grants, personal fees and non‐financial support from Abbvie; grants from Amgen; grants, personal fees and non‐financial support from Astellas; grants, personal fees and non‐financial support from BMS; grants, personal fees and non‐financial support from Jazz Pharmaceuticals; grants from Iqvia; personal fees and non‐financial support from Novartis; grants from MaatPharma; personal fees and non‐financial support from Servier; and personal fees from Takeda. Arnaud Pigneux: Grant/Research Support: Astellas and Roches; Speaker's Bureau: AbbVie, Astellas, Gilead, Pfizer, Roche and Sanofi; Consultant: AbbVie, Agios, BMS, Gilead, Jazz Pharma, Novartis, Pfizer, Roche and Takeda. Sarah Bertoli: Jazz Pharmaceuticals, Daiichi‐Sankyo, Sanofi, Astellas, BMS, Abbvie and Pfizer. Pierre‐Yves Dumas: Daiichi‐Sankyo, Jazz Pharmaceutical, Astellas, Abbvie, Celgene and Janssen."